LRRC10B Inhibitors
The LRRC10B protein, subject to modulation by a diverse array of inhibitors, is positioned at the nexus of key cellular pathways, playing a critical role in cellular responses and signaling cascades. LRRC10B, a member of the Leucine-Rich Repeat Containing (LRRC) family, is implicated in diverse cellular functions, though its precise mechanisms of action remain to be fully elucidated. This protein is integral to cellular processes, and its modulation represents a focal point for investigation into cellular responses. The LRRC10B inhibitors under scrutiny exhibit a range of mechanisms targeting crucial cellular pathways. Y-27632, a Rho-associated protein kinase (ROCK) inhibitor, perturbs the RhoA/ROCK signaling axis. This modulation has the potential to influence LRRC10B by inducing alterations in the ROCK pathway, which is intricately linked to cytoskeletal dynamics and cellular motility. The TGF-beta receptor inhibitors, SB-431542 and CAY10603, act on the transforming growth factor-beta (TGF-beta) signaling pathway. LRRC10B's indirect modulation through alterations in TGF-beta signaling underscores its role in cellular responses to this critical pathway.
Wortmannin and LY294002, targeting the phosphoinositide 3-kinase (PI3K)/Akt pathway, present additional avenues for LRRC10B modulation. As integral components of intracellular signaling, these inhibitors interfere with crucial signaling cascades, potentially modulating LRRC10B expression or activity through the intricate web of PI3K/Akt signaling. Expanding the scope to other MAPK pathway inhibitors, SP600125 and U0126 contribute to the toolkit for LRRC10B modulation. These inhibitors potentially influence LRRC10B through alterations in downstream MAPK signaling cascades. AZD8055, an mTOR inhibitor, and JSH-23, an NF-κB inhibitor, present additional dimensions to LRRC10B modulation by affecting the mTOR and NF-κB pathways, respectively. In conclusion, this diverse array of LRRC10B inhibitors provides a sophisticated toolkit for dissecting the regulation of LRRC10B, shedding light on potential avenues for further research into the intricate signaling networks in which this protein is intricately involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor influencing RhoA/ROCK signaling. Y-27632 modulates the ROCK pathway, potentially modulating LRRC10B indirectly. The RhoA/ROCK pathway regulates cytoskeletal dynamics and cellular processes, and alterations induced by Y-27632 may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $97.00 | 6 | |
TGF-beta receptor inhibitor affecting TGF-beta signaling. SB-431542 disrupts TGF-beta-mediated pathways, which can indirectly influence LRRC10B given its involvement in cellular responses to TGF-beta. This inhibitor can potentially alter the downstream signaling cascades and cellular processes that contribute to the regulation of LRRC10B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor affecting the PI3K/Akt pathway. Wortmannin interferes with intracellular signaling, potentially modulating LRRC10B indirectly. The PI3K/Akt pathway is vital in cellular functions, and alterations induced by Wortmannin may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/Akt pathway. LY294002 interferes with a key signaling pathway, potentially modulating LRRC10B indirectly. The PI3K/Akt pathway plays a crucial role in cell survival and proliferation, and alterations induced by LY294002 may impact LRRC10B expression or activity through intricate cellular processes. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $183.00 $754.00 | 8 | |
p38 MAPK inhibitor targeting the MAPK pathway. GSK650394 interferes with downstream signaling, potentially modulating LRRC10B indirectly. The MAPK pathway regulates diverse cellular processes, and alterations induced by GSK650394 may impact the expression or activity of LRRC10B through complex signaling networks. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor targeting the MAPK pathway. PD98059 interferes with downstream signaling, potentially modulating LRRC10B indirectly. The MAPK pathway regulates various cellular processes, and alterations induced by PD98059 may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src family kinase inhibitor affecting signaling pathways. PP2 modulates intracellular signaling, potentially influencing LRRC10B indirectly. Src family kinases are involved in various cellular processes, and alterations induced by PP2 may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor targeting the MAPK pathway. SP600125 disrupts JNK signaling, potentially modulating LRRC10B indirectly. The MAPK pathway is interconnected with various cellular processes, and alterations induced by SP600125 may impact the expression or activity of LRRC10B through complex signaling networks. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
mTOR inhibitor affecting the mTOR pathway. AZD8055 interferes with mTOR signaling, potentially modulating LRRC10B indirectly. The mTOR pathway plays a crucial role in cell growth and metabolism, and alterations induced by AZD8055 may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
NF-κB inhibitor affecting the NF-κB pathway. JSH-23 modulates NF-κB signaling, potentially influencing LRRC10B indirectly. The NF-κB pathway regulates various cellular processes, and alterations induced by JSH-23 may impact the expression or activity of LRRC10B through intricate signaling networks. | ||||||